Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$2.42 -6.9%	$2.24	$0.40 ▼ $3.10	$209.62M	2.05	2.22 million shs	1.54 million shs
EOLS Evolus	$9.48 -2.6%	$9.76	$8.67 ▼ $17.82	$627.35M	0.97	762,600 shs	852,343 shs
FBRX Forte Biosciences	$10.55 -7.9%	$10.35	$4.11 ▼ $28.68	$75.41M	2.97	173,621 shs	96,634 shs
MTEM Molecular Templates		$0.00	$0.00 ▼ $1.59	$1K	1.53	5.37 million shs	N/A
TXMD TherapeuticsMD	$1.18 -1.7%	$1.27	$0.70 ▼ $2.44	$13.89M	0.59	160,801 shs	12,413 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	-6.92%	-2.81%	-14.18%	+354.46%	+84.73%
EOLS Evolus	-2.57%	+2.27%	-7.42%	-0.63%	-13.42%
FBRX Forte Biosciences	-7.86%	-23.61%	-16.27%	+100.95%	+51,615.69%
MTEM Molecular Templates	0.00%	0.00%	0.00%	0.00%	-99.99%
TXMD TherapeuticsMD	-1.67%	+5.36%	-1.67%	+19.22%	-32.57%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTMX CytomX Therapeutics	4.2623 of 5 stars	3.5	1.0	0.0	4.7	2.9	1.7	1.3
EOLS Evolus	3.9144 of 5 stars	3.5	0.0	0.0	3.5	2.5	3.3	0.6
FBRX Forte Biosciences	3.5262 of 5 stars	3.5	5.0	0.0	0.0	3.5	1.7	0.6
MTEM Molecular Templates	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	0.8576 of 5 stars	0.0	2.0	0.0	0.0	3.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	3.00	Buy	$5.33	120.39% Upside
EOLS Evolus	3.00	Buy	$23.75	150.53% Upside
FBRX Forte Biosciences	3.00	Buy	$61.00	478.20% Upside
MTEM Molecular Templates	0.00	N/A	N/A	N/A
TXMD TherapeuticsMD	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest EOLS, CTMX, FBRX, MTEM, and TXMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	FBRX Forte Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$61.00
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
5/8/2025	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
4/17/2025	EOLS Evolus	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$138.10M	1.41	$0.34 per share	7.18	($0.01) per share	-242.00
EOLS Evolus	$266.27M	2.30	N/A	N/A	$0.09 per share	105.33
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$8.21 per share	N/A
MTEM Molecular Templates	$23.48M	0.00	N/A	N/A	$0.78 per share	0.00
TXMD TherapeuticsMD	$1.76M	7.76	N/A	N/A	$2.37 per share	0.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	$31.87M	$0.48	5.04	N/A	N/A	28.22%	-553.71%	32.21%	8/14/2025 (Estimated)
EOLS Evolus	-$50.42M	-$0.89	N/A	N/A	N/A	-20.40%	-759.04%	-20.14%	7/30/2025 (Estimated)
FBRX Forte Biosciences	-$35.48M	-$16.29	N/A	N/A	N/A	N/A	-149.15%	-114.25%	8/13/2025 (Estimated)
MTEM Molecular Templates	-$8.12M	-$2.70	N/A	N/A	N/A	-61.35%	-260.50%	-46.90%	N/A
TXMD TherapeuticsMD	-$2.18M	N/A	0.00	∞	N/A	-114.07%	-7.86%	-5.46%	8/11/2025 (Estimated)

Latest EOLS, CTMX, FBRX, MTEM, and TXMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	EOLS Evolus	-$0.09	N/A	N/A	N/A	$82.18 million	N/A
5/15/2025	Q1 2025	FBRX Forte Biosciences	-$0.89	-$1.37	-$0.48	-$1.37	N/A	N/A
5/13/2025	Q1 2025	TXMD TherapeuticsMD	N/A	-$0.06	N/A	-$0.06	N/A	$0.39 million
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
MTEM Molecular Templates	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	1.73	1.73
EOLS Evolus	22.00	2.34	2.16
FBRX Forte Biosciences	N/A	5.22	5.22
MTEM Molecular Templates	N/A	1.56	1.56
TXMD TherapeuticsMD	N/A	2.64	2.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
EOLS Evolus	90.69%
FBRX Forte Biosciences	77.63%
MTEM Molecular Templates	95.47%
TXMD TherapeuticsMD	30.74%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	6.60%
EOLS Evolus	5.90%
FBRX Forte Biosciences	5.90%
MTEM Molecular Templates	13.90%
TXMD TherapeuticsMD	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
EOLS Evolus	170	64.48 million	60.67 million	Optionable
FBRX Forte Biosciences	5	6.58 million	6.20 million	Optionable
MTEM Molecular Templates	260	6.58 million	5.67 million	No Data
TXMD TherapeuticsMD	420	11.57 million	11.31 million	Optionable

EOLS, CTMX, FBRX, MTEM, and TXMD Headlines

Recent News About These Companies

Marlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street Journal

June 29, 2025 | wsj.com

Mayne Pharma Files Legal Complaint Against TherapeuticsMD

June 1, 2025 | tipranks.com

TherapeuticsMD Announces First Quarter 2025 Financial Results

May 13, 2025 | businesswire.com

TherapeuticsMD Inc. stock rises Monday, still underperforms market

May 12, 2025 | marketwatch.com

TherapeuticsMD Inc. stock outperforms competitors despite losses on the day

April 8, 2025 | marketwatch.com

TherapeuticsMD Announces Full Year 2024 Financial Results

March 27, 2025 | businesswire.com

TherapeuticsMD, Inc. (TXMD) Latest Press Releases & Corporate News - Yahoo Finance

March 26, 2025 | finance.yahoo.com

TherapeuticsMD Inc’s Stock Drama: Could This Be a Game-Changer for TXMD Investors?

January 7, 2025 | bovnews.comB

TherapeuticsMD Inc (TXMD) Stock: A Deeper Look at Its True Potential

January 3, 2025 | bovnews.comB

TherapeuticsMD Inc. stock remains steady Friday, still outperforms market

December 27, 2024 | marketwatch.com

TherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gains

November 23, 2024 | marketwatch.com

TherapeuticsMD Shifts Focus with Lower Q3 Losses

November 14, 2024 | markets.businessinsider.com

TherapeuticsMD Reports Reduced Losses Amid Strategic Shift

November 14, 2024 | markets.businessinsider.com

TherapeuticsMD Announces Third Quarter 2024 Financial Results

November 13, 2024 | finance.yahoo.com

TherapeuticsMD Inc. stock remains steady Monday, underperforms market

November 12, 2024 | marketwatch.com

TherapeuticsMD (NASDAQ:TXMD) Stock, Option Chain

November 6, 2024 | benzinga.com

TherapeuticsMD Inc. stock remains steady Wednesday, underperforms market

November 6, 2024 | marketwatch.com

TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors despite daily gains

October 22, 2024 | marketwatch.com

TherapeuticsMD Inc. stock remains steady Thursday, underperforms market

October 17, 2024 | marketwatch.com

TherapeuticsMD Inc. stock remains steady Friday, underperforms market

October 11, 2024 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOLS, CTMX, FBRX, MTEM, and TXMD Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$2.42 -0.18 (-6.92%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$2.44 +0.02 (+0.83%)

As of 07/11/2025 07:44 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Evolus NASDAQ:EOLS

$9.48 -0.25 (-2.57%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$9.45 -0.03 (-0.32%)

As of 07/11/2025 05:42 PM Eastern

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Forte Biosciences NASDAQ:FBRX

$10.55 -0.90 (-7.86%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$10.68 +0.13 (+1.18%)

As of 07/11/2025 04:26 PM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Molecular Templates NASDAQ:MTEM

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

TherapeuticsMD NASDAQ:TXMD

$1.18 -0.02 (-1.67%)

Closing price 07/11/2025 03:53 PM Eastern

Extended Trading

$1.20 +0.02 (+1.69%)

As of 07/11/2025 07:49 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time